CLINICAL PRACTICE GUIDELINE

## 참고 문헌

1.  Zelenitsky S, Barns L, Findlay I, 등 . Analysis of microbiological trends in peritoneal dialysis–related peritonitis from 1991 to 1998. Am J Kidney Dis 2000; 36:1009–1013
2.  Khairullah Q, Provenzano R, Tayeb J, 등 . Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patients. Perit Dial Int 2002; 22:339–344
3.  Gucek A, Bren AF, Hergouth V, 등 . Cefazolin and netilmicin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis. Adv Perit Dial 1997; 13:218–220
4.  Lye WC, Wong PL, van der Straaten JC, 등 . A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Adv Perit Dial 1995; 11:179–181
5.  Lye WC, van der Straaten JC, Leong SO, 등 . Once–daily intraperitoneal gentamicin is effective therapy for gram–negative CAPD peritonitis. Perit Dial Int 1999; 19:357–360
6.  Schaefer F, Klaus G, Muller–Wiefel DE, 등 . Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis–associated peritonitis. The Mid–European Pediatric Peritoneal Dialysis Study Group (MEPPDPS). J Am Soc Nephrol 1999; 10:136–145
7.  Baker RJ, Senior H, Clemenger M, 등 . Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41:670–675
8.  Lui SL, Cheng SW, Ng F, 등 . Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function. Kidney Int 2005; 68:2375–2380
9.  Leung CB, Szeto CC, Chow KM, 등 . Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis—a randomized controlled trial. Perit Dial Int 2004; 24:440–446
10. Wong KM, Chan YH, Cheung CY, 등 . Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis–associated peritonitis. Am J Kidney Dis 2001; 38:127–131
11. Goffin E, Herbiet L, Pouthier D, 등 . Vancomycin and ciprofloxacin: systemic antibiotic administration for peritoneal dialysis–associated peritonitis. Perit Dial Int 2004; 24:433–439
12. Cheng IK, Fang GX, Chau PY, 등 . A randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD. Perit Dial Int 1998; 18:371–375
13. Lye WC, Lee EJ, van der Straaten J. Intraperitoneal vancomycin/oral pefloxacin versus intraperitoneal vancomycin/gentamicin in the treatment of continuous ambulatory peritoneal dialysis peritonitis. Perit Dial Int 1993; 13 Suppl 2:S348–350
14. Yeung SM, Walker SE, Tailor SA, 등 . Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. Perit Dial Int 2004; 24:447–453
15. Chan MK, Cheng IK, Ng WS. A randomized prospective trial of three different 항생제 s of treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1990; 15:155–159
16. Lima RC, Barreira A, Cardoso FL, 등 . Ciprofloxacin and cefazolin as a combination for empirical initial therapy of peritoneal dialysis–related peritonitis: five-year follow-up. Perit Dial Int 2007; 27:56–60
17. Kobayashi K, Nakamoto H, Okada S, 등 . Efficacy and safety of meropenem plus tobramycin followed by meropenem plus vancomycin for treating peritonitis in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial 2006; 22:65–68
18. Perez–Fontan M, Rosales M, Fernandez F, 등 . Ciprofloxacin in the treatment of gram-negative bacterial peritonitis in patients undergoing CAPD. Perit Dial Int 1991; 11:233–236
19. Boyce NW, Wood C, Thomson NM, 등 . Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis—a prospective, randomized comparison of intermittent v continuous therapy. Am J Kidney Dis 1988; 12:304–306
20. Low CL, Bailie GR, Evans A, 등 . Pharmacokinetics of once–daily IP gentamicin in CAPD patients. Perit Dial Int 1996; 16:379–384
21. Low CL, Gopalakrishna K, Lye WC. Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2000; 11:1117–1121
22. Manley HJ, Bailie GR, Frye R, 등 . Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. J Am Soc Nephrol 2000; 11:1310–1316
23. Manley HJ, Bailie GR, Frye RF, 등 . Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int 2001; 21:378–385
24. Manley HJ, Bailie GR, Frye R, 등 . Intermittent intravenous piperacillin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int 2000; 20:686–693
25. Park SH, Lee DH, Cho YJ, 등 . Causative organisms and patterns of antibiotics sensitivity of CAPD peritonitis in different dialysis centers. Korean J Med 2003; 64:682–689
26. Oh KH, Kim SG, Kim JS, 등 . Empiric Therapy with Cefazolin and Ceftazidime (or Aminoglycoside) is Effective as the Initial Choice for the Treatment of Peritoneal Dialysis Related Peritonitis. Korean J Nephrol 2005; 24:204–214

<PAGE>38
Clinical Practice Guideline for CAPD peritonitis